{
  "id": "61f5f777882a024a10000018",
  "type": "summary",
  "question": "What is the mechanism of action of Etesevimab?",
  "ideal_answer": "Etesevimab is a neutralizing antibody indicated for treatment of coronavirus disease 2019 (COVID-19) in patients with early mild or moderate disease.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/34537363",
    "http://www.ncbi.nlm.nih.gov/pubmed/34555986",
    "http://www.ncbi.nlm.nih.gov/pubmed/34006961",
    "http://www.ncbi.nlm.nih.gov/pubmed/34514598",
    "http://www.ncbi.nlm.nih.gov/pubmed/33972256",
    "http://www.ncbi.nlm.nih.gov/pubmed/34374951",
    "http://www.ncbi.nlm.nih.gov/pubmed/34504497",
    "http://www.ncbi.nlm.nih.gov/pubmed/34511939",
    "http://www.ncbi.nlm.nih.gov/pubmed/34433754"
  ],
  "snippets": [
    {
      "text": "Two antibodies (bamlanivimab and etesevimab) have just been approved by the FDA.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34511939",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Bamlanivimab and etesevimab are neutralizing antibodies indicated for treatment of coronavirus disease 2019 (COVID-19) in patients with early mild or moderate disease. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34514598",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The mAbs used were: Bamlanivimab alone (four patients), Bamlanivimab/Etesevimab (23 patients) and Casirivimab/Imdevimab (five patients).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34537363",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Bamlanivimab and etesevimab are monoclonal antibodies to SARS-CoV-2.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34555986",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Population Pharmacokinetics and Pharmacodynamics of the Neutralizing Antibodies Bamlanivimab and Etesevimab in Patients With Mild to Moderate COVID-19 Infection",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34514598",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "A Narrative Review of the Clinical Practicalities of Bamlanivimab and Etesevimab Antibody Therapies for SARS-CoV-2",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34374951",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Bamlanivimab and etesevimab are neutralizing antibodies indicated for treatment of coronavirus disease 2019 (COVID-19) in patients with early mild or moderate disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34514598",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Bamlanivimab and etesevimab are monoclonal antibodies (mAbs) that target the SARS-CoV-2 spike protein and block entry of SARS-CoV-2 in host cells.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34504497",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "For example, bamlanivimab and etesevimab, which are newly designed monoclonal antibodies against the surface spike protein S1 subunit receptor-binding domain (RBD) of SARS-CoV-2, have a significant effect on reducing the viral load and the hospitalization rate of patients with mild COVID-19.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34433754",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "l antibodies. Bamlanivimab and etesevimab are monoclonal antibodies to SARS-CoV-2.AREAS COVERED: This evaluation is of the phase 3 BLAZE-1 clinical trial, which was of bamlanivimab plus etesevimab in adult ambulatory participants with a risk factor for, and mild t",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34555986",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Tolerability, Safety, Pharmacokinetics, and Immunogenicity of a Novel SARS-CoV-2 Neutralizing Antibody, Etesevimab, in Chinese Healthy Adults: a Randomized, Double-Blind, Placebo-Controlled, First-in-Human Phase 1 Study.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33972256",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "We have re-engineered six anti-SARS-CoV-2 antibodies using the human p53 tetramerization domain, including three clinical trials antibodies casirivimab, imdevimab and etesevimab.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34006961",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": []
}